Review
Rev Diabet Stud,
2008,
5(2):73-94 |
DOI 10.1900/RDS.2008.5.73 |
Targeting Incretins in Type 2 Diabetes: Role of GLP-1 Receptor Agonists and DPP-4 Inhibitors
Richard E. Pratley, Matthew Gilbert
Diabetes and Metabolism Translational Medicine Unit, University of Vermont College of Medicine, Burlington, VT, USA
Address correspondence to: Richard E. Pratley, e-mail: richard.pratley@uvm.edu
Manuscript submitted May 25, 2008; resubmitted August 11, 2008; accepted August 13, 2008.
Keywords: type 2 diabetes, GLP-1 analog, incretin, exenatide, DPP-4, liraglutide, sitagliptin, vildagliptin
Abstract
Until recently, the pathogenesis of type 2 diabetes mellitus (T2DM) has been conceptualized in terms of the predominant defects in insulin secretion and insulin action. It is now recognized that abnormalities in other hormones also contribute to the development of hyperglycemia. For example, the incretin effect, mediated by glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP), is attenuated in T2DM. Intravenous administration of GLP-1 ameliorates hyperglycemia in patients with T2DM, but an extremely short half-life limits its utility as a therapeutic agent. Strategies to leverage the beneficial effects of GLP-1 include GLP-1 receptor agonists or analogs or dipeptidyl peptidase-4 (DPP-4) inhibitors—agents that act by slowing the inactivation of endogenous GLP-1 and GIP. The GLP-1 agonist exenatide has been shown to improve HbA1c and decrease body weight. However, exenatide is limited by its relatively short pharmacologic half-life, various gastrointestinal (GI) side effects, and the development of antibodies. Studies of a long-acting exenatide formulation suggest that it has improved efficacy and also promotes weight loss. Another prospect is liraglutide, a once-daily human GLP-1 analog. In phase 2 studies, liraglutide lowered HbA1c by up to 1.7% and weight by approximately 3 kg, with apparently fewer GI side effects than exenatide. DPP-4 inhibitors such as sitagliptin and vildagliptin result in clinically significant reductions in HbA1c, and are weight neutral with few GI side effects. This review will provide an overview of current and emerging agents that augment the incretin system with a focus on the role of GLP-1 receptor agonists and DPP-4 inhibitors.
Fulltext:
HTML
, PDF
(2.5 MB)
This article has been cited by other articles:
|
Role of incretin therapy at various stages of diabetes
Cernea S
Rev Diabet Stud 2011. 8(3):323-338
|
|
|
Incretin therapy - present and future
Garber AJ
Rev Diabet Stud 2011. 8(3):307-322
|
|
|
Alogliptin: a review of its use in the management of type 2 diabetes mellitus
Scott LJ
Drugs 2010. 70(15):2051-2072
|
|
|
GIP: an inconsequential incretin or not?
Pratley RE
Diabetes Care 2010. 33(7):1691-1692
|
|
|
Switching to once-daily liraglutide from twice-daily exenatide further improves glycemic control in patients with type 2 diabetes using oral agents
Buse JB, Sesti G, Schmidt WE, Montanya E, Chang CT, Xu Y, Blonde L, Rosenstock J, Liraglutide Effect Action in Diabetes-6 Study Group
Diabetes Care 2010. 33(6):1300-1303
|
|
|
Advances in research on glucagon-like peptide-1 and its analogues
Xue S, Liu Z
Pharmaceut Care Res 2010. 10(5):321-324
|
|
|
The use of exenatide in severely burned pediatric patients
Mecott GA, Herndon DN, Kulp GA, Brooks NC, Al-Mousawi AM, Kraft R, Rivero HG, Williams FN, Branski LK, Jeschke MG
Crit Care 2010. 14(4):R153
|
|
|
Sitagliptin: a review of its use in the management of type 2 diabetes mellitus
Dhillon S
Drugs 2010. 70(4):489-512
|
|
|
Partnering with patients to improve therapeutic outcomes: incretin-based therapy for type 2 diabetes
Nadeau DA
Postgrad Med 2010. 122(3):7-15
|
|
|
Incretin analogues that have been developed to treat type 2 diabetes hold promise as a novel treatment strategy for Alzheimer’s disease
Holscher C
Recent Pat CNS Drug Discov 2010. 5(2):109-117
|
|
|
Managing type 2 diabetes in the primary care setting: beyond glucocentricity
Kuritzky L
Am J Med Sci 2010. 340(2):133-143
|
|
|
Historical overview of incretin based therapies
Bhansali A, Maji D, Rao PV, Banerjee S, Kumar H
J Assoc Physicians India 2010. 58(Suppl):15-17
|
|
|
Utilities and disutilities for attributes of injectable treatments for type 2 diabetes
Boye KS, Matza LS, Walter KN, Van Brunt K, Palsgrove AC, Tynan A
Eur J Health Econ 2010. Mar 12, epub ahead of print
|
|
|
Glucagon-like peptide-1 (GLP-1) inhibits advanced glycation end product (AGE)-induced up-regulation of VCAM-1 mRNA levels in endothelial cells by suppressing AGE receptor (RAGE) expression
Ishibashi Y, Matsui T, Takeuchi M, Yamagishi S
Biochem Biophys Res Commun 2010. 391(3):1405-1408
|
|
|
Reaching HbA1c goals with saxagliptin in combination with other oral antidiabetic drugs
LaSalle JR
Postgrad Med 2010. 122(1):144-152
|
|
|
Chemical modification of Class II G protein-coupled receptor ligands: Frontiers in the development of peptide analogs as neuroendocrine pharmacological therapies
Chapter MC, White CM, Deridder A, Chadwick W, Martin B, Maudsley S
Pharmacol Ther 2010. 125(1):39-54
|
|
|
The role of basal insulin and glucagon-like peptide-1 agonists in the therapeutic management of type 2 diabetes - a comprehensive review
Garg SK.
Diabetes Technol Ther 2010. 12(1):11-24
|
|
|
Incretins, incretinmimetics, inhibitors
Bayon C, Barriga MA, Litwak L
Rev Argent Endocrinol Metab 2010. 47(1):36-51
|
|
|
A review of efficacy and safety data regarding the use of liraglutide, a once-daily human glucagon-like peptide 1 analogue, in the treatment of type 2 diabetes mellitus
Montanya E, Sesti G
Clin Ther 2009. 31(11):2472-2488
|
|
|
Incretin-based therapies: review of the outpatient literature with implications for use in the hospital and after discharge
Bode B, Amin A
Hosp Pract 2009. 37(1):249
|
|
|
Dipeptidyl peptidase IV(DPP IV): a novel emerging target for the treatment of type 2 diabetes
Wu J, Chen Y, Shi X, Gu W
J Nanjing Med Univ 2009. 23(4):228-235
|
|
|
Effect of exendin-4 on the expression of survivin in pancreas in streptozotocin-induced diabetic mice
Xu MT, Zhang Y, Chen LH, Wu MC, Yan L, Cheng H
Chin Pharmacol Bull 2009. 25(7):932-934
|
|
|
Glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized clinical trials
Monami M, Marchionni N, Mannucci E
Eur J Endocrinol 2009. 160(6):909-917
|
|
|
Islet G protein-coupled receptors as potential targets for treatment of type 2 diabetes
Ahrén B
Nat Rev Drug Discov 2009. 8(5):369-385
|
|
|
Treatment for diabetes mellitus with GLP-1 (glucagon-like peptide-1) receptor agonists
Miyagawa J, Miuchi M, Namba M
J Jpn Diabetes Soc 2009. 52(6):427-431
|
|
|
Ethnic and gender differences regarding the insulin-blood pressure relationship
Palmer IM, Schutte AE, Huisman HW
Diabetes Res Clin Pract 2009. 85(1):102-110
|
|
|
Present and prospective pharmacotherapy for the management of patients with type 2 diabetes
Corsino L, Cox ME, Rowell J, Green JB
Clin Med Ther 2009. 1:1103-1119
|
|
|
DPP4 inhibitors: from sitagliptin monotherapy to the new alogliptin-pioglitazone combination therapy
Argyrakopoulou G, Doupis J
Adv Ther 2009. 26(3):272-280
|
|
|
Dipeptidyl-peptidase IV and B-type natriuretic peptide. From bench to bedside
Vanderheyden M, Bartunek J, Goethals M, Verstreken S, Lambeir AM, De Meester I, Scharpe S
Clin Chem Lab Med 2009. 47(3):248-252
|
|
|
Taspoglutide
Arjona A
Drugs Future 2008. 33(11):938
|
|
|
The new science of GLP-1: effects beyond glucose control
Pratley RE
Johns Hopkins Adv Stud Med 2008. 8(11):393-399
|
|
|